ViralClear appoints former Celgene exec as chair, dusts off long-shelved hepatitis C drug for Covid-19 trial

The company, part of BioSig Technologies, aims to run a Phase II study of the drug, merimepodib, which had previously failed in a Phase IIb HCV study run by Vertex Pharmaceuticals. The company hopes the drug's mechanism could prove effective against SARS-CoV-2.